Healthtech funding in H1 2023
European Healthtech startup funding raised during H1 2023.
In H1 2023, 302 European Healthtech companies closed 309 funding rounds and raised €2.7B in equity funding (excluding debt and grants), down 34.1% versus H1 2022. Debt rounds added €228M. UK led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 20 Nov 2026.
Equity funding
€2.7B
-34.1% vs H1 2022 · excl. debt & grants · +€228M debt
Funding rounds
309
-6.1% vs H1 2022
Companies
302
Top country
UK
Rank among sectors
#4
9.9% of sector funding
Debt financing
€228M
7.7% of total
Top-10 round share
36.2%
of disclosed capital
Rounds ≥ €100M
7
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H1 2023 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €538M | 66 |
| Feb | €580M | 54 |
| Mar | €517M | 57 |
| Apr | €443M | 45 |
| May | €585M | 47 |
| Jun | €309M | 40 |
Top countries
by € raisedHealthtech — top countries by capital, H1 2023 — interactive chart.
Data table
| Healthtech — top countries by capital, H1 2023 | |
|---|---|
| UK | €589M |
| Germany | €541M |
| France | €527M |
| Switzerland | €432M |
| Denmark | €192M |
| Spain | €108M |
| Sweden | €107M |
| Netherlands | €105M |
Stage mix
by € raisedHealthtech — stage mix, H1 2023 — interactive chart.
Data table
| Healthtech — stage mix, H1 2023 | |
|---|---|
| Other | €1.0B |
| Series B | €488M |
| Series C | €467M |
| Series A | €427M |
| Debt | €228M |
| Seed | €155M |
| Series D+ | €122M |
| Grant | €48M |
| Pre-Seed | €24M |
| Crowdfunding | €3.1M |
| Early VC | €2.5M |
| Growth/Late | €1.0M |
Exits & M&A
22 Acquisition · 1 Merger23 exits · €246M disclosed.
| Verogen | Acquisition | Jan 2023 | €140M |
| Odin Vision | Acquisition | Jun 2023 | €77M |
| Diamond Whites | Acquisition | Feb 2023 | €30M |
Top deals
largest disclosed rounds in H1 2023| Company | Stage | Date | Amount |
|---|---|---|---|
| Evotec | Debt | Feb 2023 | €150M |
| DistalMotion | Other | Apr 2023 | €137M |
| Amolyt Pharma | Series C | Jan 2023 | €129M |
| Hemab Therapeutics | Series B | Feb 2023 | €127M |
| Ascend | Other | May 2023 | €121M |
| Noema Pharma | Series B | Mar 2023 | €105M |
| Patient21 | Series C | May 2023 | €100M |
| Humble | Other | Jun 2023 | €74M |
| Complement Therapeutics | Series A | Apr 2023 | €72M |
| Corwave | Series C | Jun 2023 | €61M |
| SoniVie | Series C | Jan 2023 | €56M |
| Moon Surgical | Other | May 2023 | €51M |
| Tissium | Series D+ | May 2023 | €50M |
| NewBiologix | Series A | May 2023 | €46M |
| Grey Wolf Therapeutics | Series B | Jan 2023 | €45M |
Top investors
most active in H1 2023, by deal count- High-Tech Gründerfonds (HTGF)11 deals
- European Innovation Council (EIC)9 deals
- Sofinnova Partners8 deals
- Innovate UK7 deals
- Bpifrance5 deals
- Novo Holdings5 deals
- Octopus Ventures5 deals
- Andera Partners4 deals
- Calm Storm Ventures4 deals
- Clave Capital4 deals